US Animal Biotechnology Market Size Likely to Surpass at a CAGR of 7.1% By 2033

As per the current market research conducted by the CMI Team, the US Animal Biotechnology Market size is expected to record a CAGR of 7.1% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 13,019.9 Million. By 2033, the valuation is anticipated to reach USD 24,138.7 Million.

US Animal Biotechnology Market: Growth Factors and Dynamics

• Improvement in technology: The emergence of new genetic and genomic technology and proteomic engineering technology has brought many new and innovative biotechnology products and services. These developments enhance animal health and productivity and move toward more accurate and effective management.

• Need for More Animal Protein: The requirement to increase consumption of animal products like meat and dairy, on which more attention is focused on developing high-tech biotechnological solutions. Thus, since such demand has to be met, the industry has also witnessed a growing need to maximize livestock efficiencies, enhance feed conversions, and maintain a consistent high-grade animal protein supply.

• Concern About Animal Health: The advancements in biotechnology create new vistas for improving animal health, the prevention of mass diseases, improvement in food safety, and the reduction of superbugs. New vaccines, diagnostics, and therapies are developed.

• Support of Regulating Bodies and Investment: The United States government and other relevant bodies actively encourage funding and commercialization of biotechnology research through grants, subsidies, and several regulations. Such encouragement pushes them to commit resources and grow in the industry, creating a conducive atmosphere for innovation and market growth.

• New and Re-emerging Animal Infectious Diseases and Biosecurity: New or re-emerging diseases in animals, among other things, must be battled with improved biosecurity to avoid outbreaks and animal health. A psychological understanding of the impact of such diseases on humans will help in effective planning to prevent and fight these threats.

• Sustainable Environmental Practices: The pressure has ever grown on an available biotechnological alternative to develop more agricultural, environmentally friendly practices. These involved reducing the negative impacts of livestock production and improving feed conversion efficiency to improve the sustainability of the whole farm.

• Artificial Intelligence and Data Analytics in Animal Biotechnology: Application of AI, beyond data analytics, transforms the animal biotech industry. It allowed more precise observation of animal health. It provided predictive analysis for disease outbreaks, thus enabling more optimized practice in breeding, which, in turn, resulted in more effective and informed livestock operations management.

US Animal Biotechnology Market: Partnership and Acquisitions

• In 2022, Hester Bio, known for poultry vaccines, is expanding into pet care. The company plans to introduce products in fields such as dermatology, nutrition, grooming, anti-infective, and niche areas to broaden the scope of its activities and, thus, its target audience.

• In 2022, Cadila Pharma launched ‘ThRabis,’ a first-of-its-kind three-dose rabies vaccine, in the market. This is the first time rabies has been effectively combated with recombinant nanoparticle-based G protein technology and virus-like particle technology.

Report Scope

US Animal Biotechnology Market: COVID-19 Analysis

The COVID-19 pandemic has significantly impacted the US Animal Biotechnology Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• COVID-19 global pandemic: The COVID-19 global pandemic seriously disrupted the supply chains that covered raw material supplies and manufacturing processes necessary to produce animal biotechnology products. Hence, biotech firms lost further and took a longer time to recover.

• Lower Investment and Research Delays: Apart from the operational woes stated above, the financial impact attributed to the COVID-19 pandemic was also there. Reduced investments in animal biotechnology R&D were made during that time. Most projects remained stalling and terminated for many years because of reduced funds and more emphasis on urgent needs.

• Health and Safety: As the outbreak of the pandemic ensured that people gave much more attention to health and safety, not only regarding humans but also animal health, this has led to the way more resources being committed to the development of biotechnology-based methods of disease prevention and better real-time animal tracking systems.

• Stronger Supply Chains: Global players are strengthening and diversifying supply chains to avoid future disruptions. Concentrating on local production, such players invest in regions and build stronger supply networks.

• Fast pace Adoption of Digital Technologies: Adoption of new digital technologies like remote resolution as several sectors are on the lookout due to the COVID-19 pandemic. This trend can be observed as many of the biotechnology companies are employing a digital approach for R&D activities at a high scale. Moreover, synergy, enhanced flexibility, and greater efficiency have also catalyzed the adoption of more advanced digital devices.

• Government and Policy Support: The policies of the U.S. regarding animal biotechnology and the majority of various industries that were exposed to the pandemic were upheld by the government. This involved not only funding and securing resources for research but also changing the cancerological stance in such a way that would converting America’s economy into a post-COVID environment.

• Increased Emphasis on Sustainable Practices Economically: Increased Emphasis on Sustainable Practices Economically, it captured the necessity for sustainable agriculture during the time of COVID-19 outbreak. As a result, there is greater demand for biotechnological innovations that are more sustainable, particularly in terms of feed conversion ratios and reductions in the environmental impact of the livestock industry.

In conclusion, the COVID-19 pandemic has had a mixed impact on the US Animal Biotechnology Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the US Animal Biotechnology Market:

• Zoetis Inc.
• Elanco Animal Health Incorporated
• Merck Animal Health
• Boehringer Ingelheim Animal Health
• Cargill Inc.
• BASF SE
• Alltech Inc.
• Heska Corporation
• Genus plc
• Neogen Corporation
• IDEXX Laboratories Inc.
• Aratana Therapeutics Inc.
• Vetoquinol S.A.
• Merial (part of Boehringer Ingelheim)
• Dechra Pharmaceuticals PLC
• Others

The US Animal Biotechnology Market is segmented as follows:

By Product

• Diagnostics Tests
• Vaccines and Drugs
• Reproductive and Genetic
• Feed Additives
• Others

By Application          

• Diagnosis of Animal Diseases
• Treatment of Animal Diseases
• Preventive Care of Animals
• Drug Development
• Others

By End User

• Veterinary Laboratories
• Point-of-Care Testing/In-house Testing
• Veterinary Hospitals & Clinics
• Others